Should I Buy Alcoa Stock?
Alcoa (AA) finds itself in an interesting position in early…
Sell
36
FCX Quote, Financials, Valuation and Earnings
Last price:
$38.18
Seasonality move
:
2.13%
Day range:
$37.20 - $38.13
52-week range:
$33.98 - $55.24
Dividend yield:
1.57%
P/E ratio:
29.56x
P/S ratio:
2.16x
P/B ratio:
3.12x
Volume:
13M
Avg. volume:
17.1M
1-year change:
-19.44%
Market cap:
$54.8B
Revenue:
$25.5B
EPS (TTM):
$1.29
Analysts' Opinion
-
Consensus RatingFreeport-McMoRan has received a consensus rating of Hold. The company's average rating is a Hold based on 7 Buy ratings, 8 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $47.44, Freeport-McMoRan has an estimated upside of 24.42% from its current price of $38.13.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $25.00 representing 34.44% downside risk from its current price of $38.13.
Fair Value
-
According to the consensus of 16 analysts, Freeport-McMoRan has 24.42% upside to fair value with a price target of $47.44 per share.
FCX vs. S&P 500
-
Over the past 5 trading days, Freeport-McMoRan has underperformed the S&P 500 by -10.4% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Freeport-McMoRan does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Freeport-McMoRan revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Freeport-McMoRan reported revenues of $5.7B.
Earnings Growth
-
Freeport-McMoRan earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Freeport-McMoRan reported earnings per share of $0.19.
Enterprise value:
71B
EV / Invested capital:
--
Price / LTM sales:
2.16x
EV / EBIT:
9.83x
EV / Revenue:
2.79x
PEG ratio (5yr expected):
18.77x
EV / Free cash flow:
30.19x
Price / Operating cash flow:
23.42x
Enterprise value / EBITDA:
7.50x
Gross Profit (TTM):
$7.7B
Return On Assets:
3.48%
Net Income Margin (TTM):
7.42%
Return On Equity:
6.66%
Return On Invested Capital:
5.01%
Operating Margin:
21.73%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $22.8B | $22.9B | $25.5B | $5.9B | $5.7B | |
| Gross Profit | $7.7B | $7.2B | $7.7B | $2B | $1.4B | |
| Operating Income | $7B | $6.2B | $6.9B | $1.7B | $1.2B | |
| EBITDA | $9.3B | $8.6B | $9.5B | $2.4B | $1.8B | |
| Diluted EPS | $2.37 | $1.27 | $1.29 | $0.27 | $0.19 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $9.3B | $14.8B | $15.6B | $14.1B | $13.3B | |
| Total Assets | $42.1B | $48B | $51.1B | $52.5B | $54.8B | |
| Current Liabilities | $3.4B | $5.9B | $6.3B | $5.8B | $5.5B | |
| Total Liabilities | $23.5B | $25B | $26.2B | $25.2B | $26.1B | |
| Total Equity | $18.7B | $23B | $24.9B | $27.3B | $28.8B | |
| Total Debt | $9.7B | $9.5B | $10.6B | $9.4B | $8.9B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $5.1B | $5.3B | $7.2B | $1.3B | $1.4B | |
| Cash From Investing | -$3.4B | -$5B | -$5B | -$1.4B | -$1.2B | |
| Cash From Financing | -$1.6B | -$2.7B | -$3.3B | -$424M | -$1.5B | |
| Free Cash Flow | $1.7B | $455M | $2.4B | -$42M | $197M | |
FCX
Sector
Market Cap
$54.8B
$17.8M
Price % of 52-Week High
69.03%
60.85%
Dividend Yield
1.57%
0%
Shareholder Yield
--
1.21%
1-Year Price Total Return
-19.44%
-13.51%
Beta (5-Year)
1.710
0.927
Dividend yield:
1.57%
Annualized payout:
$0.60
Payout ratio:
45.79%
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$40.09
200-day SMA
Sell
Level
$43.23
Bollinger Bands (100)
Sell
Level
37.13 - 43.15
Chaikin Money Flow
Buy
Level
709.9M
20-day SMA
Sell
Level
$38.90
Relative Strength Index (RSI14)
Sell
Level
46.92
ADX Line
Sell
Level
15.17
Williams %R
Neutral
Level
-74.7191
50-day SMA
Sell
Level
$38.23
MACD (12, 26)
Buy
Level
0.36
25-day Aroon Oscillator
Buy
Level
48
On Balance Volume
Neutral
Level
1.6B
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.3245)
Sell
CA Score
(Annual)
Level (-0.5023)
Buy
Beneish M-Score
(Annual)
Level (-3.2747)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (-2.0244)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Freeport-McMoRan owns stakes in 10 copper mines, led by its 49% ownership of the Grasberg copper and gold operations in Indonesia, 55% of the Cerro Verde mine in Peru, and 72% of Morenci in Arizona. It sold around 1.2 million metric tons of copper (its share) in 2024, making it the one of the world’s largest copper miners by volume. It also sold about 900,000 ounces of gold, mostly from Grasberg, and 70 million pounds of molybdenum. It had about 25 years of copper reserves at end December 2024. we expect it to sell similar amounts of copper midcycle in 2029, though we expect gold volumes to decline to about 700,000 ounces then due to falling production at Grasberg.
Stock Forecast FAQ
In the current month, FCX has received 7 Buy ratings 8 Hold ratings, and 1 Sell ratings. The FCX average analyst price target in the past 3 months is $47.44.
-
Where Will Freeport-McMoRan Stock Be In 1 Year?
According to analysts, the consensus estimate is that Freeport-McMoRan share price will rise to $47.44 per share over the next 12 months.
-
What Do Analysts Say About Freeport-McMoRan?
Analysts are divided on their view about Freeport-McMoRan share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Freeport-McMoRan is a Sell and believe this share price will drop from its current level to $25.00.
-
What Is Freeport-McMoRan's Price Target?
The price target for Freeport-McMoRan over the next 1-year time period is forecast to be $47.44 according to 16 Wall Street analysts, 7 of them rate the stock a Buy, 1 rates the stock a Sell, and 8 analysts rate the stock a Hold.
-
Is FCX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Freeport-McMoRan is a Hold. 8 of 16 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of FCX?
You can purchase shares of Freeport-McMoRan via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Freeport-McMoRan shares.
-
What Is The Freeport-McMoRan Share Price Today?
Freeport-McMoRan was last trading at $38.18 per share. This represents the most recent stock quote for Freeport-McMoRan. Yesterday, Freeport-McMoRan closed at $38.13 per share.
-
How To Buy Freeport-McMoRan Stock Online?
In order to purchase Freeport-McMoRan stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Nu Holdings Stock Be in 2030?
Despite fast growth, high profitability and an extraordinary runway ahead,…
Is it Too Late to Buy United Airlines Stock?
United Airlines (NASDAQ:UAL) has thoroughly outpaced the broader stock market…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 37x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
42
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
78
GATE alert for Apr 2
Marblegate Acquisition [GATE] is up 86.64% over the past day.
Buy
52
NUTX alert for Apr 2
Nutex Health [NUTX] is up 5.41% over the past day.
Buy
75
CORT alert for Apr 2
Corcept Therapeutics [CORT] is down 8.84% over the past day.
